Viking Therapeutics, Inc. (NASDAQ: VKTX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 9.23% | Shs Outstand | 116.65M | Perf Week | -8.62% |
| Market Cap | 3.42B | Forward P/E | - | EPS next Y | -4.39 | Insider Trans | -1.75% | Shs Float | 113.39M | Perf Month | -12.02% |
| Enterprise Value | 2.93B | PEG | - | EPS next Q | -1.07 | Inst Own | - | Short Float | 19.57% | Perf Quarter | -3.07% |
| Income | -360.00M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 9.74 | Perf Half Y | -12.49% |
| Sales | 0.00 | P/B | 8.39 | EPS next Y | 4.78% | ROA | -102.47% | Short Interest | 22.19M | Perf YTD | -16.54% |
| Book/sh | 3.50 | P/C | 6.82 | EPS next 5Y | - | ROE | -94.56% | 52W High | 43.15 -31.96% | Perf Year | 23.93% |
| Cash/sh | 4.30 | P/FCF | - | EPS past 3/5Y | - | ROIC | -135.79% | 52W Low | 22.96 27.87% | Perf 3Y | 93.41% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 4.66% 4.40% | Perf 5Y | 341.50% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -361.39% | Oper. Margin | 0.00% | ATR (14) | 1.48 | Perf 10Y | 2158.46% |
| Dividend Ex-Date | - | Quick Ratio | 4.72 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 32.12 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.72 | EPS Q/Q | -89.66% | SMA20 | -10.45% | Beta | 0.62 | Target Price | 91.75 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | -14.15% | Rel Volume | 0.92 | Prev Close | 29.52 |
| Employees | 65 | LT Debt/Eq | 0.00 | Earnings | Oct 28 | SMA200 | -11.91% | Avg Volume | 2.27M | Price | 29.36 |
| IPO Date | Apr 28, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 10.77% - | Net Debt/EBITDA | 0.23 | Volume | 2,082,993 | Change | -0.54% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-28-26 | Initiated | Lake Street | Buy | $89 |
| May-27-26 | Reiterated | Truist Financial | Buy | $75 → $83 |
| Apr-30-26 | Reiterated | Morgan Stanley | Overweight | $99 → $95 |
| Apr-30-26 | Reiterated | Cantor Fitzgerald | Overweight | $105 → $100 |
| Mar-12-26 | Reiterated | Jefferies | $110 → $101 | |
| Feb-12-26 | Reiterated | Morgan Stanley | Overweight | $102 → $99 |
| Nov-12-25 | Reiterated | Canaccord Genuity | Buy | $106 → $107 |
| Oct-29-25 | Reiterated | Canaccord Genuity | $106 | |
| Oct-23-25 | Reiterated | Cantor Fitzgerald | $105 | |
| Oct-23-25 | Reiterated | Morgan Stanley | Overweight | $105 → $102 |
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | — | — | |
| Gross Profit | 0 | 0 | 0 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 48 | 49 | 37 | — | — | — | — | — | — | |
| Research and Development | 345 | 102 | 64 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -393 | -151 | -101 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 34 | 41 | 15 | — | — | — | — | — | — | |
| Net Income Before Taxes | -360 | -110 | -86 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -360 | -110 | -86 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -360 | -110 | -86 | — | — | — | — | — | — | |
| Net Income | -360 | -110 | -86 | — | — | — | — | — | — | |
| EPS (Recurring) | -3.19 | -1.01 | -0.91 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.19 | -1.01 | -0.91 | — | — | — | — | — | — | |
| EPS (Diluted) | -3.19 | -1.01 | -0.91 | — | — | — | — | — | — | |
| EBITDA | -359 | -110 | -86 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 113 | 109 | 94 | — | — | — | — | — | — | |
| Market Capitalization | 3,975 | 4,386 | 1,749 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Lian Brian | President & CEO | Jul 29 '26 | Sale | 33.32 | 148,517 | 4,947,888 | 2,572,441 | Jul 29 |
| ZANTE GREG | Chief Financial Officer | Jul 29 '26 | Sale | 33.47 | 21,217 | 710,141 | 212,204 | Jul 29 |
| Mancini Marianna | Chief Operating Officer | Jul 29 '26 | Sale | 33.47 | 18,217 | 609,636 | 422,760 | Jul 29 |
| Aubuchon Neil William | Chief Commercial Officer | Mar 10 '26 | Buy | 33.50 | 4,475 | 149,913 | 4,475 | Mar 10 |
| Mancini Marianna | Chief Operating Officer | Jan 05 '26 | Sale | 32.98 | 57,661 | 1,901,406 | 409,190 | Jan 05 |
| Lian Brian | President & CEO | Jan 05 '26 | Sale | 32.96 | 233,409 | 7,692,121 | 2,499,291 | Jan 05 |
| ZANTE GREG | Chief Financial Officer | Jan 05 '26 | Sale | 32.90 | 57,661 | 1,896,969 | 189,891 | Jan 05 |
| FOEHR MATTHEW W | Director | Jan 02 '26 | Option Exercise | 3.33 | 16,000 | 53,280 | 148,036 | Jan 05 |
| FOEHR MATTHEW W | Director | Jan 02 '26 | Sale | 35.11 | 16,000 | 561,694 | 132,036 | Jan 05 |
| ZANTE GREG | Chief Financial Officer | Oct 28 '25 | Sale | 35.00 | 6,185 | 216,481 | 173,592 | Oct 28 |
| Mancini Marianna | Chief Operating Officer | Oct 28 '25 | Sale | 35.00 | 6,185 | 216,492 | 382,467 | Oct 28 |
| Lian Brian | President & CEO | Oct 28 '25 | Sale | 35.01 | 38,989 | 1,364,923 | 2,419,109 | Oct 28 |
| Rowland Charles A Jr | Director | Oct 27 '25 | Option Exercise | 5.11 | 60,000 | 306,640 | 0 | Oct 28 |
| Rowland Charles A Jr | Director | Oct 27 '25 | Sale | 35.57 | 60,000 | 2,134,278 | 30,000 | Oct 28 |
| ZANTE GREG | Chief Financial Officer | Jul 03 '25 | Sale | 27.76 | 4,266 | 118,428 | 168,660 | Jul 03 |